OxRML/AgentSLR huggingface dataset:
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 11.8 Percentage (%) (Central)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 15 / 25 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 15 to 
Country: Mali
Location: Bougouni
Setting: Population based, Unspecified
Sample size: 127
Study period: Oct 2016 - Nov 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 17.5 Percentage (%) (Central)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 7 / 40 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 15 to 
Country: Mali
Location: Kita
Setting: Population based, Unspecified
Sample size: 40
Study period: Oct 2016 - Nov 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 15 Percentage (%) (Central)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 6 / 12 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 15 to 
Country: Mali
Location: Kita
Setting: Population based, Unspecified
Sample size: 40
Study period: Oct 2016 - Nov 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 43.3 Percentage (%) (Central)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 81 / 187 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 15 to 
Country: Mali
Location: Bandiagara
Setting: Population based, Unspecified
Sample size: 187
Study period: Oct 2016 - Nov 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 15.5 Percentage (%) (Central)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 29 / 105 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 15 to 
Country: Mali
Location: Bandiagara
Setting: Population based, Unspecified
Sample size: 187
Study period: Oct 2016 - Nov 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 35.8 Percentage (%) (Central)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 39 / 109 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 15 to 
Country: Mali
Location: Diema
Setting: Population based, Unspecified
Sample size: 109
Study period: Oct 2016 - Nov 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 20.2 Percentage (%) (Central)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 22 / 53 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 15 to 
Country: Mali
Location: Diema
Setting: Population based, Unspecified
Sample size: 109
Study period: Oct 2016 - Nov 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Exponent (base 10): 0
Numerator/denominator: 51 / 179 (method: )
Population: Pregnant women, sex: Both, ages  to 
Country: France
Location: Guadeloupe
Setting: Population based, 
Sample size: 179
Study period: Apr 2016 - Mar 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 21.7 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 33 / 152 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Mixed groups, sex: Unspecified, ages 0 to 80
Country: Nigeria
Location: Abia State  University Teaching Hospital, Aba, Abia state
Setting: Hospital based, Both urban and rural areas
Sample size: 152
Study period: Dec 2020 - Nov 2021
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 18.9 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 79 / 419 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Mixed groups, sex: Unspecified, ages 0 to 80
Country: Nigeria
Location: Federal Medical Centre, Keffi, Nasarawa State.
Setting: Hospital based, Both urban and rural areas
Sample size: 419
Study period: Dec 2020 - Nov 2021
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 18.3 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 55 / 300 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Mixed groups, sex: Unspecified, ages 0 to 80
Country: Nigeria
Location: Baru-Dokp Teaching Hospital, Kaduna, Kaduna State
Setting: Hospital based, Both urban and rural areas
Sample size: 300
Study period: Dec 2020 - Nov 2021
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 19.2 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 167 / 871 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Age, Other, Region, Sex
Trimester exposed: Unspecified
Population: Mixed groups, sex: Unspecified, ages 0 to 80
Country: Nigeria
Location: Abia State  University Teaching Hospital, Aba, Abia state, Federal Medical Centre, Keffi, Nasarawa State, Baru-Dokp Teaching Hospital, Kaduna, Kaduna State
Setting: Hospital based, Both urban and rural areas
Sample size: 871
Study period: Dec 2020 - Nov 2021
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 1.4 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 4 / 295 (method: )
Population: Persons under investigation, sex: Both, ages  to 
Country: Sri Lanka
Location: Kandy
Setting: Hospital based, 
Study period: 2017 - 2019
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 9 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 17 / 300 (method: )
Population: Persons under investigation, sex: Both, ages  to 
Country: Sri Lanka
Location: Negombo
Setting: Hospital based, 
Study period: 2018 - 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 34.5 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 102 / 295 (method: )
Population: Persons under investigation, sex: Both, ages  to 
Country: Sri Lanka
Location: Kandy
Setting: Hospital based, 
Study period: 2017 - 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 42.6 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 128 / 300 (method: )
Population: Persons under investigation, sex: Both, ages  to 
Country: Sri Lanka
Location: Negombo
Setting: Hospital based, 
Study period: 2018 - 2019
Parameter: Seroprevalence - IgM (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 110 / 339 (method: )
Seroprevalence adjustment: Naive
Population: Persons under investigation, sex: Both, ages  to 
Country: United States
Location: Puerto Rico
Setting: Population based, 
Sample size: 339
Study period: Apr 2016 - Dec 2016
Parameter: Attack rate (Attack rate)
Value: 0.25 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.19 - 0.31 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Brazil
Setting: Population based, Unspecified
Study period: Apr 2015 - 31 Dec 2018
Parameter: Attack rate (Attack rate)
Value: 0.16 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.07 - 0.29 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Bolivia
Setting: Population based, Unspecified
Study period: 1 Jan 2016 - 30 Jun 2018
Parameter: Attack rate (Attack rate)
Value: 0.23 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.07 - 0.49 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Belize
Setting: Population based, Unspecified
Study period: 1 Jan 2016 - 31 Dec 2017
Parameter: Attack rate (Attack rate)
Value: 0.19 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.15 - 0.23 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Colombia
Setting: Population based, Unspecified
Study period: 9 Aug 2015 - 31 Dec 2017
Parameter: Attack rate (Attack rate)
Value: 0.09 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.02 - 0.19 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Costa Rica
Setting: Population based, Unspecified
Study period: 1 Jan 2016 - 31 Dec 2017
Parameter: Attack rate (Attack rate)
Value: 0.25 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.18 - 0.33 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Dominican Republic
Setting: Population based, Unspecified
Study period: 1 Jan 2016 - 25 Mar 2018
Parameter: Attack rate (Attack rate)
Value: 0.361 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.214 - 0.514 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Ecuador
Setting: Population based, Unspecified
Study period: 20 Dec 2015 - 23 Oct 2018
Parameter: Attack rate (Attack rate)
Value: 0.28 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.16 - 0.4 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: El Salvador
Setting: Population based, Unspecified
Study period: 22 Nov 2015 - 16 Dec 2017
Parameter: Attack rate (Attack rate)
Value: 0.23 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.16 - 0.29 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Guatemala
Setting: Population based, Unspecified
Study period: 29 Nov 2015 - 20 Oct 2018
Parameter: Attack rate (Attack rate)
Value: 0.36 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.22 - 0.49 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Honduras
Setting: Population based, Unspecified
Study period: 13 Dec 2015 - 4 Jan 2018
Parameter: Attack rate (Attack rate)
Value: 0.2 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.15 - 0.25 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Mexico
Setting: Population based, Unspecified
Study period: 28 Nov 2015 - 5 Nov 2018
Parameter: Attack rate (Attack rate)
Value: 0.12 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.06 - 0.22 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Panama
Setting: Population based, Unspecified
Study period: 22 Nov 2015 - 10 Nov 2018
Parameter: Attack rate (Attack rate)
Value: 0.33 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.21 - 0.46 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Nicaragua
Setting: Population based, Unspecified
Study period: 27 Jan 2016 - 31 Dec 2017
Parameter: Attack rate (Attack rate)
Value: 0.084 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.067 - 0.096 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Peru
Setting: Population based, Unspecified
Study period: 1 Jan 2016 - 15 Sep 2018
Parameter: Attack rate (Attack rate)
Value: 0.32 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.29 - 0.35 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: United States
Location: Puerto Rico
Setting: Population based, Unspecified
Study period: 1 Jan 2007 - 7 Jan 2017
Parameter: Attack rate (Attack rate)
Value: 0.016 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.01 - 0.025 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Brazil
Location: State of Paraná
Setting: Population based, Unspecified
Study period: Apr 2015 - 31 Dec 2018
Parameter: Attack rate (Attack rate)
Value: 0.766 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.569 - 0.942 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Brazil
Location: State of Sergipe
Setting: Population based, Unspecified
Study period: Apr 2015 - 31 Dec 2018
Parameter: Attack rate (Attack rate)
Value: 0 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0 - 0 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Mexico
Location: Federal District
Setting: Population based, Unspecified
Study period: 28 Nov 2015 - 5 Nov 2018
Parameter: Attack rate (Attack rate)
Value: 0.793 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.524 - 0.963 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Mexico
Location: State of Yucatán
Setting: Population based, Unspecified
Study period: 28 Nov 2015 - 5 Nov 2018
Parameter: Attack rate (Attack rate)
Value: 0.514 Unspecified (Median)
Exponent (base 10): 0
Uncertainty: 0.388 - 0.631 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Brazil
Location: Bahia
Setting: Population based, Unspecified
Study period: Apr 2015 - 31 Dec 2018
Parameter: Seroprevalence - MIA (Seroprevalence)
Value: 6.7 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 4.5 - 9.4 (95% CI)
Numerator/denominator: 30 / 451 (method: )
Population: Persons under investigation, sex: Both, ages  to 
Country: Fiji
Location: Central division
Setting: Population based, 
Sample size: 778
Study period: Sep 2013 - Nov 2013
Parameter: Seroprevalence - MIA (Seroprevalence)
Value: 11.9 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 4.9 - 22.9 (95% CI)
Numerator/denominator: 7 / 59 (method: )
Population: Persons under investigation, sex: Both, ages  to 
Country: Fiji
Location: Northern division
Setting: Population based, 
Sample size: 778
Study period: Sep 2013 - Nov 2013
Parameter: Seroprevalence - MIA (Seroprevalence)
Value: 9 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 5.8 - 13 (95% CI)
Numerator/denominator: 24 / 268 (method: )
Population: Persons under investigation, sex: Both, ages  to 
Country: Fiji
Location: Western division
Setting: Population based, 
Sample size: 778
Study period: Sep 2013 - Nov 2013
Parameter: Seroprevalence - MIA (Seroprevalence)
Value: 21.9 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 17.9 - 26.8 (95% CI)
Numerator/denominator: 73 / 333 (method: )
Population: Persons under investigation, sex: Both, ages  to 
Country: Fiji
Location: Central division
Setting: Population based, 
Sample size: 333
Study period: Oct 2015 - Nov 2015
Parameter: Seroprevalence - MIA (Seroprevalence)
Value:  Percentage (%) ()
Exponent (base 10): 0
Bounds: 6.1 - 25.2
Disaggregated by: Age, Sex, Time
Population: Persons under investigation, sex: Both, ages  to 
Country: Fiji
Setting: Population based, 
Study period: Sep 2013 - Nov 2015
Parameter: Seroprevalence - IgG (Seroprevalence)
Exponent (base 10): 0
Numerator/denominator: 311 / 1226 (method: )
Seroprevalence adjustment: Naive
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Cabo Verde
Setting: Population based, Unspecified
Sample size: 1226
Study period: Oct 2015 - 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Exponent (base 10): 0
Numerator/denominator: 311 / 311 (method: )
Seroprevalence adjustment: Naive
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Cabo Verde
Setting: Population based, Unspecified
Sample size: 1226
Study period: Oct 2015 - 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 80.4 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 82 / 102 (method: )
Seroprevalence adjustment: Naive
Trimester exposed: Post-partum
Population: Pregnant women, sex: Female, ages  to 
Country: Nicaragua
Location: León
Setting: Hospital based, Unspecified
Sample size: 102
Study period: 5 Feb 2017 - Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 66.4 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 89 / 134 (method: )
Seroprevalence adjustment: Naive
Trimester exposed: Post-partum
Population: Pregnant women, sex: Female, ages  to 
Country: Nicaragua
Location: León
Setting: Hospital based, Unspecified
Sample size: 134
Study period: 5 Feb 2017 - Unspecified
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 44.4 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 40 / 90 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Bahia
Setting: Hospital based, Unspecified
Sample size: 90
Study period: Mar 2015 - Feb 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 96.7 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 87 / 90 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Bahia
Setting: Hospital based, Unspecified
Sample size: 90
Study period: Mar 2015 - Feb 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 90 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 81 / 90 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Bahia
Setting: Hospital based, Unspecified
Sample size: 90
Study period: Mar 2015 - Feb 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 7.1 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 5 / 70 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Both, ages  to 
Country: Brazil
Location: Bahia
Setting: Hospital based, Unspecified
Sample size: 70
Study period: Mar 2015 - Feb 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 88.6 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 62 / 70 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Both, ages  to 
Country: Brazil
Location: Bahia
Setting: Hospital based, Unspecified
Sample size: 70
Study period: Mar 2015 - Feb 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 84.8 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 39 / 46 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Both, ages  to 
Country: Brazil
Location: Bahia
Setting: Hospital based, Unspecified
Sample size: 70
Study period: Mar 2015 - Feb 2016
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 2.69 No units (Unspecified)
Exponent (base 10): 0
Uncertainty: 2.31 - 3.11 (95% CrI)
Statistical approach: Estimated model parameter
Reproduction number method: Growth rate Unspecified
Population: General population, sex: Both, ages  to 
Country: Brazil
Location: Manaus
Setting: Population based, Unspecified
Study period: Nov 2015 - Unspecified
Parameter: Mutations - evolutionary rate (Mutations)
Value: 1.09 Substitutions/site/year (Unspecified)
Exponent (base 10): -3
Uncertainty: 0.00077 - 0.00143 (95% CrI)
Statistical approach: Estimated model parameter
Genome site: Whole genome sequence
Genomic lineage: Manaus clade
Population: General population, sex: Both, ages  to 
Country: Brazil
Location: Manaus
Setting: Population based, Unspecified
Sample size: 59
Study period: 15 Dec 2015 - Mar 2017
Parameter: Risk factors (Risk factors)
Exponent (base 10): 0
Uncertainty: 8e-04 - 0.0014 (95% CrI)
Risk factor: Other (outcome: Infection; significant: Significant; adjusted: Not adjusted; occupation: )
Population: General population, sex: Both, ages  to 
Country: Brazil
Location: Manaus
Setting: Population based, Unspecified
Study period: Unspecified
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 61.2 Percentage (%) (Unspecified)
Exponent (base 10): 0
Numerator/denominator: 287 / 469 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Post-partum
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Salvador (Hospital Geral Roberto Santos)
Setting: Population based, Unspecified
Sample size: 469
Study period: Oct 2015 - Unspecified
Parameter: Seroprevalence - IgM (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 19 / 41 (method: Naive)
Seroprevalence adjustment: Naive
Population: Persons under investigation, sex: Both, ages  to 
Country: Brazil
Location: Hospital da Restauração, Recife, Pernambuco,
Setting: Hospital based, Urban area
Sample size: 41
Study period: Nov 2015 - Apr 2016
Parameter: Human delay - Admission to care to Discharge from care (Human delay)
Value: 17 Days (Median)
Exponent (base 10): 0
Bounds: 9 - 23
Population: Persons under investigation, sex: Both, ages  to 
Country: Brazil
Location: Hospital
Setting: Hospital based, 
Sample size: 41
Study period: Nov 2015 - Apr 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 1.8 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 4 / 217 (method: Naive)
Seroprevalence adjustment: Unspecified
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: Saudi Arabia
Location: Abha
Setting: Hospital based, Unspecified
Sample size: 217
Study period: 2019 - 2020
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 1 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 2 / 217 (method: Naive)
Seroprevalence adjustment: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: Saudi Arabia
Location: Abha
Setting: Hospital based, Unspecified
Sample size: 217
Study period: 2019 - 2020
Parameter: Seroprevalence - IgG (Seroprevalence)
Value:  Percentage (%) (Unspecified)
Exponent (base 10): 0
Bounds: 0 - 21.4
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages  to 
Country: Brazil
Location: Ribeirão Preto, São Paulo State
Setting: Population based, Unspecified
Study period: Jul 2010 - May 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value:  Percentage (%) (Unspecified)
Exponent (base 10): 0
Bounds: 0 - 16.9
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages  to 
Country: Brazil
Location: Ribeirão Preto, São Paulo State
Setting: Population based, Unspecified
Study period: Jul 2010 - May 2017
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 2.3383 No units (Central)
Exponent (base 10): 0
Uncertainty: 2.1787 - 2.4877 (95% CI)
Statistical approach: Estimated model parameter
Population: General population, sex: , ages  to 
Country: France
Location: Tahiti, French Polynesia
Setting: Population based, Unspecified
Study period: Oct 2013 - Mar 2014
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 2.4977 No units (Central)
Exponent (base 10): 0
Uncertainty: 2.0424 - 3.1481 (95% CI)
Statistical approach: Estimated model parameter
Population: General population, sex: , ages  to 
Country: France
Location: Sous-le-vent Islands, French Polynesia
Setting: Population based, Unspecified
Study period: Oct 2013 - Mar 2014